Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
S O'Hagan, N Galway, MD Shields… - Drug, Healthcare and …, 2023 - Taylor & Francis
Abstract Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity
and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against …
and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against …
Pregnancy outcome after exposure to injectable ribavirin during embryogenesis
M Rezvani, G Koren - Reproductive Toxicology, 2006 - Elsevier
We describe normal pregnancy outcome in a case of first trimester exposure to injectable
ribavirin in a 36-year-old pregnant woman who received three intramuscular injections of …
ribavirin in a 36-year-old pregnant woman who received three intramuscular injections of …
[CITATION][C] Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects
S Bianca, G Ettore - Birth defects research. Part A, Clinical …, 2003 - pubmed.ncbi.nlm.nih.gov
Male periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects Male
periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects Birth …
periconceptional ribavir-ininterferon alpha-2b exposure with no adverse fetal effects Birth …
[CITATION][C] Ribavirin: is there a risk to hospital personnel? Infectious Diseases and Immunization Committee, Canadian Paediatric Society
Canadian Medical Association - CMAJ, 1991 - Can Med Assoc